drugset / Trial / NCT02723838

Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

NCT02723838

Phase 1 Withdrawn Oncolytics Biotech
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety and efficacy of intratumoral REOLYSIN® therapy alone and in combination with standard neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.

Timeline

Start
2017-02-28
Primary completion
2017-09-30
Completion
2018-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 70 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Pelareorep Other / unclassified 3e+10 unknown Other